Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2005 1
2006 1
2008 1
2013 1
2014 4
2015 2
2016 2
2018 2
2019 1
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial.
Cluver CA, Hiscock R, Decloedt EH, Hall DR, Schell S, Mol BW, Brownfoot F, Kaitu'u-Lino TJ, Walker SP, Tong S. Cluver CA, et al. BMJ. 2021 Sep 22;374:n2103. doi: 10.1136/bmj.n2103. BMJ. 2021. PMID: 34551918 Free PMC article. Clinical Trial.
PARTICIPANTS: 180 women with preterm pre-eclampsia between 26+0 to 31+6 weeks' gestation undergoing expectant management: 90 were randomised to extended release metformin and 90 to placebo. INTERVENTION: 3 g of oral extended release metformin or placebo daily, in di …
PARTICIPANTS: 180 women with preterm pre-eclampsia between 26+0 to 31+6 weeks' gestation undergoing expectant management: 90 were randomised …
Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial.
Safai N, Suvitaival T, Ali A, Spégel P, Al-Majdoub M, Carstensen B, Vestergaard H, Ridderstråle M; CIMT Trial Group. Safai N, et al. Diabet Med. 2018 Jul;35(7):944-953. doi: 10.1111/dme.13636. Epub 2018 May 2. Diabet Med. 2018. PMID: 29633349 Clinical Trial.
At follow-up, participants randomized to metformin (n = 188) had elevated levels of leucine/isoleucine and reduced carnitine, tyrosine and valine compared with placebo (n = 182). ...This association was not significant with HbA(1c) at follow-up. CONCLUSIONS: Metf …
At follow-up, participants randomized to metformin (n = 188) had elevated levels of leucine/isoleucine and reduced carnitine, tyro …
Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
Arrieta O, Zatarain-Barrón ZL, Turcott JG, Barrón F, Yendamuri S, Cardona AF, Rosell R. Arrieta O, et al. JAMA Oncol. 2022 Mar 1;8(3):477-479. doi: 10.1001/jamaoncol.2021.7015. JAMA Oncol. 2022. PMID: 35024769 Free PMC article. Clinical Trial.
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
Li L, Jiang L, Wang Y, Zhao Y, Zhang XJ, Wu G, Zhou X, Sun J, Bai J, Ren B, Tian K, Xu Z, Xiao HL, Zhou Q, Han R, Chen H, Wang H, Yang Z, Gao C, Cai S, He Y. Li L, et al. Clin Cancer Res. 2019 Dec 1;25(23):6967-6975. doi: 10.1158/1078-0432.CCR-19-0437. Epub 2019 Aug 14. Clin Cancer Res. 2019. PMID: 31413010 Clinical Trial.
PURPOSE: Preclinical and retrospective studies suggested a role for metformin in sensitizing patients who have diabetes with non-small cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitors (TKIs). ...The estimated 1-year PFS rates were 41.2% [95% confidence in …
PURPOSE: Preclinical and retrospective studies suggested a role for metformin in sensitizing patients who have diabetes with non-smal …
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR, Lee AJ, Mayor JG, Rustia EL, Abdulrasool LI, Wise AL, Dailey B, DeChenne S, Walker LN, Alley SC, Endres CJ. Topletz-Erickson AR, et al. J Clin Pharmacol. 2021 Apr;61(4):461-471. doi: 10.1002/jcph.1750. Epub 2020 Sep 28. J Clin Pharmacol. 2021. PMID: 32989831 Free PMC article. Clinical Trial.
In vitro, tucatinib inhibited OCT2-, MATE1-, and MATE2-K-mediated transport of metformin, with IC(50) values of 14.7, 0.340, and 0.135 M, respectively. ...Renal function was assessed by measuring glomerular filtration rate (GFR; based on iohexol plasma clearance) and endog …
In vitro, tucatinib inhibited OCT2-, MATE1-, and MATE2-K-mediated transport of metformin, with IC(50) values of 14.7, 0.340, and 0.13 …
Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.
Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, Rajpal D, Spivak A, Brown JR, Nunez DJ. Napolitano A, et al. PLoS One. 2014 Jul 2;9(7):e100778. doi: 10.1371/journal.pone.0100778. eCollection 2014. PLoS One. 2014. PMID: 24988476 Free PMC article. Clinical Trial.
In this study we evaluated T2DM subjects on and off metformin monotherapy to characterize the gut-based mechanisms of metformin. Subjects were studied at 4 time points: (i) at baseline on metformin, (ii) 7 days after stopping metformin, (iii) when fast …
In this study we evaluated T2DM subjects on and off metformin monotherapy to characterize the gut-based mechanisms of metformin …
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Karlsson HK, Hällsten K, Björnholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lönnqvist F, Nuutila P, Zierath JR. Karlsson HK, et al. Diabetes. 2005 May;54(5):1459-67. doi: 10.2337/diabetes.54.5.1459. Diabetes. 2005. PMID: 15855334 Clinical Trial.
The effect of metformin or rosiglitazone monotherapy versus placebo on insulin signaling and gene expression in skeletal muscle of patients with newly diagnosed type 2 diabetes was determined. ...Insulin-mediated whole-body and leg muscle glucose uptake was enhanced 36 and …
The effect of metformin or rosiglitazone monotherapy versus placebo on insulin signaling and gene expression in skeletal muscle of pa …
Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS).
Tsilchorozidou T, Batterham RL, Conway GS. Tsilchorozidou T, et al. Clin Endocrinol (Oxf). 2008 Dec;69(6):936-42. doi: 10.1111/j.1365-2265.2008.03285.x. Epub 2008 Apr 24. Clin Endocrinol (Oxf). 2008. PMID: 18435831 Clinical Trial.
However, the mechanisms by which metformin causes weight loss are unclear. We sought to determine whether circulating levels of the anorectic gut hormone peptide tyrosine tyrosine (PYY) show any correlation with metformin-induced weight loss. ...Intere …
However, the mechanisms by which metformin causes weight loss are unclear. We sought to determine whether circulating levels of the a …
Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study.
Preiss D, Rankin N, Welsh P, Holman RR, Kangas AJ, Soininen P, Würtz P, Ala-Korpela M, Sattar N. Preiss D, et al. Diabet Med. 2016 Nov;33(11):1569-1574. doi: 10.1111/dme.13097. Epub 2016 Mar 3. Diabet Med. 2016. PMID: 26887663 Clinical Trial.
METHODS: In the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) study (NCT00723307), 173 individuals without Type 2 diabetes, but with coronary disease, were randomized to metformin (n=86) or placebo (n=87) for 18 months. ...These changes are inde …
METHODS: In the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) study (NCT00723307), 173 individuals without Type …
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Fasano M, Della Corte CM, Capuano A, Sasso FC, Papaccio F, Berrino L, Ciardiello F, Morgillo F. Fasano M, et al. Clin Lung Cancer. 2015 Jan;16(1):57-9. doi: 10.1016/j.cllc.2014.06.010. Epub 2014 Aug 17. Clin Lung Cancer. 2015. PMID: 25242667 Clinical Trial.
We present the rationale and study design of the METAL (METformin in Advanced Lung cancer) trial (EudraCT number: 2014-000349-59), a multicenter, open label phase II study, designed to evaluate the safety and activity of metformin combined with erlotinib as second-l …
We present the rationale and study design of the METAL (METformin in Advanced Lung cancer) trial (EudraCT number: 2014-000349-59), a …
18 results